Ocrelizumab (Ocrevus) for people with primary progressive multiple sclerosis
In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether treatment with ocrelizumab (trade name: Ocrevus) in addition to best supportive care (BSC) has any advantages or disadvantages for people with primary progressive multiple sclerosis (PPMS). The following results apply only to patients who have early-stage PPMS.
The manufacturer provided one study. All participants received best supportive care. On top of that, 486 people were given ocrelizumab, and 239 people took a placebo (dummy drug). The following results were found after about four years and four months: